% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Buchert:280229,
author = {Buchert, Ralph and Drzezga, Alexander and Schreckenberger,
Mathias and Langen, Karl Josef and Meyer, Philipp T},
collaboration = {Medicine, Working Group Nuclear Neuroimaging of the German
Society of Nuclear},
title = {{N}eurobildgebung mit {SPECT} und {PET} in {D}eutschland:
{E}rgebnisse der 1. {U}mfrage zur nuklearmedizinischen
{N}eurobildgebung in {D}eutschland 2023.},
journal = {Nuklearmedizin},
volume = {64},
number = {4},
issn = {0029-5566},
address = {Stuttgart},
publisher = {Thieme},
reportid = {DZNE-2025-00907},
pages = {250 - 261},
year = {2025},
abstract = {The advent of disease-modifying therapies for
neurodegenerative diseases may result in a growing demand
for nuclear neuroimaging procedures presenting opportunities
but also challenges to the nuclear medicine community.
Whether capacity and expertise in Germany are sufficient to
meet an increasing demand for nuclear neuroimaging is under
discussion. Against this background, the Neuroimaging
Working Group of the German Society of Nuclear Medicine
initiated the first survey on the status of nuclear
neuroimaging in Germany in 2023. 82 institutions
participated in the survey: 33 practices, 15 community
hospitals, 34 university hospitals. Primary findings were
the following. In practices, brain scans are less frequently
performed than in hospitals and are often limited to
dopamine transporter SPECT. Brain PET is mainly performed in
hospitals, and in community hospitals it is often restricted
to FDG PET. Nevertheless, availability of amyloid PET with
well-certified quality can be taken for granted. Thus,
access to amyloid PET will not be a major bottleneck for new
treatments of Alzheimer's disease. Adequate reimbursement
and clear anchoring in clinical guidelines have the greatest
potential to advance nuclear neuroimaging in Germany.
Clinical dopamine transporter SPECT is largely in agreement
with procedure guidelines. An area for improvement is the
limited availability of MR images to avoid misinterpretation
of structural/vascular lesions as nigrostriatal
degeneration. The survey provides the first systematic
assessment of the status of nuclear neuroimaging in Germany.
It underscores the capacity of the German nuclear medicine
community to meet an increasing demand for neuroimaging
procedures, its adherence to procedure guidelines and
identifies topics for improvement.},
keywords = {Germany / Humans / Tomography, Emission-Computed,
Single-Photon: statistics $\&$ numerical data /
Positron-Emission Tomography: statistics $\&$ numerical data
/ Neuroimaging: statistics $\&$ numerical data /
Neuroimaging: methods / Surveys and Questionnaires / Brain:
diagnostic imaging},
cin = {AG Boecker},
ddc = {610},
cid = {I:(DE-2719)1011202},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40233814},
pmc = {pmc:PMC12328034},
doi = {10.1055/a-2566-1487},
url = {https://pub.dzne.de/record/280229},
}